The demand for sepsis diagnostic products is expected to grow mainly due to factors such as the increasing public-private funding for sepsis diagnostic research activities, the growing burden of infectious diseases, the rising number of sepsis incidences, and growing government initiatives for creating sepsis awareness. 

The COVID-19 pandemic had a moderately positive effect on the sales of diagnostics products for sepsis. The global spread of covid-19 and the emerging cases of sepsis among covid-19 patients are likely to increase the demand for rapid diagnosis, accelerating the utilization of instruments, reagents, & assay kits for detection of sepsis.  

The current COVID-19 pandemic has highlighted the risk faced by older adults, who are more susceptible to complications, including acute respiratory distress syndrome, usually due to pneumonia, which increases the risk of developing sepsis. Thus, increasing the need for early diagnosis of sepsis among patients with covid-19 infections. 

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=92673155  

Sepsis is a very difficult condition to diagnose and the risk of mortality increases by 7.6% with a delay of even 1 minute in antibiotic administration in septic shock patients with hypertension. Thus, increasing the need for the rapid diagnosis of sepsis to reduce the delay of antibiotic therapy among patients with sepsis. 

Many sepsis diagnostic manufacturers are expanding their product offering in point of care technology rapidly detecting the sepsis, reducing the overall turnaround time of diagnosis. . The BACTEC Plus, BacT/Alert, and BACTEC FX blood culturing instruments manufactured by BD Company (US) is an automated microbial detection system offering a rapid diagnosis of sepsis in the turnaround time of three hours. 

Sepsis is a life-threatening condition that needs to be diagnosed and treated at the earliest with the help of skilled healthcare professionals. The shortage of skilled professionals is a major concern worldwide; only 50% of patients with severe sepsis transported by the EMS system have a paramedic. The lack of trained paramedics affects each phase of patient care—sepsis awareness, screening patients for the presence of sepsis, and making an appropriate 

The sepsis diagnostics market, by product, the market is segmented into blood culture media, assays & reagent kits, instruments, and software. The blood culture media segment accounted for the largest share of market during the forecast period. This share can be attributed to the growing utilization of blood culture media by hospitals & pathology laboratories for the diagnosis of sepsis coupled with an increase in the availability of blood culture media in the market. 

The prominent players operating in the global sepsis diagnostics market include bioMérieux (France), Becton, Dickinson and Company (US), Danaher Corporation (US), T2 Biosystems (US), Luminex (US), Roche Diagnostics (Switzerland), Thermo Fisher Scientific (US), Bruker Corporation (US), Abbott Laboratories (US), Immunexpress (Australia), Axis-Shield Diagnostics (UK), Quidel Corporation (US), Siemens Healthineers (Germany), EKF Diagnostics (UK), Seegene Inc., (South Korea), Boditech Med (South Korea), Alifax S.r.l. (Italy), AdvanDx  (US), (US), Immunexpress (Australia), and Axis-Shield Diagnostics (UK).